

For Immediate Release

**MEDX HEALTH CORP.**

**NEWS RELEASE**

TSX Venture Symbol: MDX

CUSIP #: 585090

**MEDX HEALTH CORP. RESULTS FOR THE FIRST QUARTER OF FISCAL 2013.**

Mississauga, Ontario, May 28, 2013 – MedX Health Corp. (“MDX” or the “Company”) (TSX-V: MDX) reported today its financial and operational results for the First Quarter of fiscal 2013. All amounts are in Canadian dollars unless otherwise stated.

**First Quarter Financial Highlights**

The highlights for MDX, on a consolidated basis, are:

- Consolidated revenue decreased by 41% to \$119,429 in Q1 2013 compared to \$203,172 in Q1 2012;
- Consolidated Gross Profit decreased 47% to \$64,370 in Q1 2013 compared to \$121,555 in Q1 2012;
- Consolidated operating expenses decreased by 14% to \$413,038 in Q1 2013 compared to \$479,346 in Q1 2012;
- 3% decrease in consolidated net loss before income taxes to a loss of \$348,668 in Q1 2013 compared to net loss of \$357,791 in Q1 2012;

Steven Guillen, CEO, said: “The First Quarter of Fiscal 2013 presented many challenges while we were in the process of changing many aspects of our business strategy. We have significantly developed and re-aligned our strategic approach to marketing which we believe will lead to major developments during fiscal 2013 as we bring our products, especially the MoleMate™ units, to the market through new channels. We look forward to the balance of fiscal 2013 with great confidence.” Mr. Guillen also noted that Cease Trade Orders previously imposed as a consequence of the late filing of the Company’s 2012 Audited annual Financial Statements and MD&A have been lifted and that while the Company’s listing on the TSX-V is currently suspended, an Application for Reinstatement is being pursued; the Company will announce the result of that Application as soon as it is available.

A summary of the Results for the First Quarters of fiscal 2013 and 2012 (in thousands of dollars, except per share earnings) is included in the Table below:

	2013 – Q1	2012 – Q1
Revenues	119	203
Cost of goods sold	55	82
Gross profit (loss)	64	122
Comprehensive loss	(349)	(358)
Per share	(0.01)	(0.01)
Total assets	415	691

**Consolidated Unaudited Interim Financial Statements**

**NOTE TO READER:** The following unaudited interim financial statements are extracted from the complete unaudited interim financial statements of the Company for the Three Months ended March 31, 2013, which have been filed with the Management’s Discussion and Analysis. References to “accompanying Notes” refer to the Notes to the unaudited interim financial statements for the Three Months ended March 31, 2013 and 2012, which are filed with the Company’s documents, and can be found on [www.sedar.com](http://www.sedar.com) to which the reader is referred.

**MEDX HEALTH CORP.**  
**Consolidated Statement of Financial Position**

(Expressed in Canadian dollars)  
(unaudited)

As at,	<u>March 31, 2013</u>	<u>December 31, 2012</u>
<b>ASSETS</b>	<b>\$</b>	<b>\$</b>
<b>CURRENT ASSETS</b>		
Cash	6,148	16,051
Trade and other receivables (note 5)	79,744	127,450
Inventory (note 6)	104,733	97,677
Prepaid expenses and deposits	9,341	11,150
	<u>199,966</u>	<u>252,328</u>
PROPERTY, PLANT AND EQUIPMENT (note 7)	31,355	33,158
INTANGIBLE ASSETS (note 8)	183,717	190,217
	<u><b>415,038</b></u>	<u><b>475,703</b></u>
<b>LIABILITIES</b>		
<b>CURRENT LIABILITIES</b>		
Trade and other payables (note 9)	4,153,522	3,985,297
Demand loans	779,394	779,394
Convertible debentures	174,262	171,118
	<u>5,107,178</u>	<u>4,935,809</u>
<b>SHAREHOLDERS' DEFICIENCY</b>		
CAPITAL STOCK (note 10)	12,693,913	12,577,279
EQUITY PORTION OF CONVERTIBLE DEBENTURES	16,906	16,906
WARRANTS	1,388,124	1,388,124
SHARE BASED PAYMENTS	1,171,224	1,171,224
DEFICIT	<u>(19,962,307)</u>	<u>(19,613,639)</u>
	<u>(4,692,140)</u>	<u>(4,460,106)</u>
	<u><b>415,038</b></u>	<u><b>475,703</b></u>

**NATURE OF BUSINESS AND GOING CONCERN (Notes 1 and 2)**  
**SUBSEQUENT EVENTS (Note 15)**

Approved by the Board of Directors on May 28, 2013

(signed) Gary Van Nest, Director

(signed) Steven Guillen, Director

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**NOTICE TO READER: These unaudited interim financial statements have not been reviewed by the Company's Auditors**

**MEDX HEALTH CORP.**  
**Consolidated Statement of Comprehensive Loss**  
**For the quarters ended March 31, 2013 and 2012**  
(Expressed in Canadian dollars)  
(Unaudited)

	<b>Three months ended</b>	
	<b>Mar 31, 2013</b>	<b>Mar 31, 2012</b>
	<b>\$</b>	<b>\$</b>
<b>SALES</b>	119,429	203,172
<b>COST OF SALES</b>	<u>55,059</u>	<u>81,616</u>
<b>GROSS PROFIT</b>	64,370	121,555
<b>EXPENSES</b>		
Selling, general and administrative	354,326	426,831
Research and development costs	-	6,410
Interest accretion on convertible debentures	3,144	-
Interest on demand loans and convertible debentures	28,873	-
Foreign exchange loss (gain)	1,712	(3,780)
Depreciation of property, plant and equipment	1,849	1,983
Amortization of intangible assets	6,500	8,500
Loss on debt settlement with common shares (note 10)	<u>16,634</u>	<u>39,402</u>
	<u>413,038</u>	<u>479,346</u>
<b>COMPREHENSIVE LOSS</b>	<u>(348,668)</u>	<u>(357,791)</u>
<b>Comprehensive loss per common shares - basic and diluted</b>	<u>(0.01)</u>	<u>(0.01)</u>
<b>Weighted average number of Common Shares outstanding - basic and fully diluted</b>	<u>39,949,894</u>	<u>35,702,848</u>

The accompanying notes are an integral part of these consolidated financial statements.

**NOTICE TO READER: These unaudited interim financial statements have not been reviewed by the Company's Auditors**

**MEDX HEALTH CORP.**  
**Consolidated Statement of Cash Flows**  
**For the quarters ended March 31, 2013 and 2012**  
(Expressed in Canadian dollars)  
(Unaudited)

	<b>Three months ended</b>	
	<b>Mar 31, 2013</b>	<b>Mar 31, 2012</b>
	<b>\$</b>	<b>\$</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Comprehensive loss	(348,668)	(357,791)
Adjustments for non-cash items:		
Depreciation of property, plant and equipment	1,849	1,983
Amortization of intangible assets	6,500	8,500
Foreign exchange loss	1,712	-
Loss on debt settlement with common shares	16,634	39,402
Interest accretion on convertible debentures	3,144	3,144
Accrued interest on demand loans and convertible debentures	28,873	30,430
Trade debt settled with common shares	100,000	98,506
Net change in non-cash operating working capital items:		
Trade and other receivables	47,706	39,343
Inventory	(7,056)	10,561
Prepaid expenses and deposits	1,809	(11,455)
Trade payables and other payables	137,594	116,079
Cash flow (used in) from operating activities	<u>(9,903)</u>	<u>(21,299)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchases of property, plant and equipment	-	(3,886)
Purchase of intangible assets	-	(28,199)
Cash flow used in investing activities	<u>-</u>	<u>(32,085)</u>
<b>NET INCREASE (DECREASE) IN CASH</b>	(9,903)	(53,383)
Cash, beginning of period	<u>16,051</u>	<u>58,705</u>
<b>CASH, END OF PERIOD</b>	<u><u>6,148</u></u>	<u><u>5,322</u></u>

The accompanying notes are an integral part of these consolidated financial statements.

**NOTICE TO READER: These unaudited interim financial statements have not been reviewed by the Company's Auditors**

**MEDX HEALTH CORP.****Consolidated Statements of Changes in Shareholders' Deficiency**

	<u>Capital Stock</u>						
	Number	Amount	Equity portion of convertible debentures	Warrants	Share based payments	Deficit	Total
		\$	\$	\$	\$	\$	\$
Balance, January 1, 2012	35,356,453	12,150,281	25,676	1,370,725	1,029,424	(19,074,415)	(4,498,309)
Common shares issued for debt settlement	3,862,693	335,228		17,399	141,800		494,427
Convertible debenture exercise	332,000	83,000					83,000
Value transfer on convertible debenture exercise		8,770	(8,770)				-
Comprehensive loss						(539,224)	(539,224)
Balance, December 31, 2012	39,551,146	12,577,279	16,906	1,388,124	1,171,224	(19,613,639)	(4,460,106)
Common shares issued for debt settlement	1,794,365	116,634					116,634
Comprehensive loss						(348,668)	(248,668)
Balance, March 31, 2013	41,345,511	12,693,913	16,906	1,388,124	1,171,224	(19,962,307)	(4,592,140)

The accompanying notes are an integral part of these consolidated financial statements.

**NOTICE TO READER: These unaudited interim financial statements have not been reviewed by the Company's Auditors**

For further information, please contact Louie Canitano, President and Chief Operating Officer at (905) 670-4428. Email inquiries should be made to [canitano@medxhealth.com](mailto:canitano@medxhealth.com) and the company website is located at [www.medxhealth.com](http://www.medxhealth.com). Inquiries by direct mail should be addressed to; MedX Health 220 Superior Blvd., Mississauga, Ontario, L5T 2L2

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*Certain information set out in this News Release constitutes forward-looking information. Forward-looking statements (often, but not always, identified by the use of words such as “expect”, “may”, “could”, “anticipate” or “will” and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements are based upon the opinions, expectations and estimates of management of MDX as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Although MDX believes that the expectations reflected in the forward-looking statements set out in this press release or incorporated herein by reference are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements of MDX contained in this News Release, or incorporated herein by reference, are expressly qualified, in their entirety, by this cautionary statement and the risk factors contained in MDX’s current annual information form available at [www.sedar.com](http://www.sedar.com).*